Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Ex-BoE man highlights alleged ‘insider trading bonanza’ at Astra

Ex-BoE man highlights alleged ‘insider trading bonanza’ at Astra

A former senior adviser to the Bank of England has highlighted unusual trading patterns in AstraZeneca before it publicly disclosed a takeover approach from Pfizer.

AstraZeneca revealed on Monday that Ian Read, chairman and chief executive of Pfizer, had first contacted it on 25 November 2013 to ‘discuss a combination’.

AstraZeneca subsequently staged ‘an exploratory meeting’ with Pfizer on 5 January 2014 in New York. Neither event was announced to markets.

In the six months until November 2013, AstraZeneca’s share price had lagged the wider FTSE 100, losing 1.5% while the index gained 4.7%.

Since November, AstraZeneca’s stock has surged 14.3% while the FTSE 100 has dropped 1.6%.

The divergence between the two was most marked in January when AstraZeneca rose by 8% and the index fell by 3.5%.

January also brought a spike in the trading of AstraZeneca shares. Between May 2013 and December 2013, trading volumes were consistently around £1.5 billion per month. This leapt to £2.5 billion in January, and has remained above £2 billion since then.

Since 31 October 2013, AstraZeneca has released three sets of financial results. Each of these featured double-digit percentage declines in both the company’s profits and earnings per share.

In a blog today entitled ‘AstraZeneca: Insider Trading Bonanza???’ for the Cass Business School, where he is a lecturer, Peter Hahn supposed that regulators would take a keen interest in these patterns, although there is not concrete evidence of insider dealing.

‘The lack of an AstraZeneca board announcement will certainly be questioned, but it looks like a dead certainty that many a regulator and lawyer will be very busy,’ commented Hahn, who from 2009 until March 2014 was a senior adviser to the Bank of England focused on the Prudential Regulation Authority.

A spokesperson for AstraZeneca declined to comment.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Video special: what Scottish DFMs think of SNP election flop

Video special: what Scottish DFMs think of SNP election flop

As delegates gathered for Citywire Scotland, we asked them their take on the election.

Play Keith Skeoch: 'passive has a part to play'

Keith Skeoch: 'passive has a part to play'

In the third part our series, Skeoch outlines his vision for Standard Aberdeen.

2 Comments Play Keith Skeoch: why I believe markets will make 'substantial returns'

Keith Skeoch: why I believe markets will make 'substantial returns'

In an exclusive interview, Standard Life CEO Keith Skeoch tells us why he takes an optimistic view on markets just about everywhere.

Read More
Your Business: Cover Star Club

Profile: Rathbones' fund boss on spotting emerging talent

1 Comment Profile: Rathbones' fund boss on spotting emerging talent

A great fund manager is really easy to spot, says Mike Webb, chief executive of Rathbones Unit Trust Management

Wealth Manager on Twitter